This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the
treatment p53 wild-type malignant salivary gland cancer.
Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and
was terminated early.
Part 2 is a single arm study (APG-115 monotherapy).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ascentage Pharma Group Inc. University of Michigan Rogel Cancer Center
Collaborators:
Ascentage Pharma Group Inc. University of Michigan